Lecia V. Sequist, MD, MPH | Authors


Understanding EGFR Resistance in Patients With MET-Amplified NSCLC

October 24, 2019

Lecia V. Sequist, MD, MPH, director, says that oncologists have developed a better understanding of what causes resistance to EGFR inhibitors in patients with non–small cell lung cancer through preclinical studies and biopsies. MET amplification was found to be one of the major causes of resistance to newer generation EGFR-targeted drugs.